Clinic of Anesthesia and Reanimation, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey.
Department of Anatomy, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
Microsc Res Tech. 2024 Mar;87(3):506-515. doi: 10.1002/jemt.24452. Epub 2023 Nov 7.
Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. The aim of this study is to investigate the teratogenic effects of sugammadex on neural tube and embryonic development in early chick embryos. In this study, 50 0-day fertile specific non-pathogenic (SPF) eggs were used. Fifty eggs were divided into 5 different groups, each consisting of 10 pieces. While no substance was given to the control group at the 28th hour of the study, 4 different doses of sugammadex were administered to the experimental groups, respectively 2, 4, 8, 16 mg/kg. Cranio-caudal lengths of embryos, somite numbers, average number of argyrophilic nucleolar regulatory regions (AgNOR) per nucleus, total AgNOR area/total nuclear area (TAA/NA) ratios, Caspase-3 H-Score results, and presence of neural tube defect were compared among the groups. While the mean cranio-caudal lengths, somite counts, TAA/NA ratios and AgNOR counts of the embryos were found to be statistically significantly lower than the control group, Caspase-3 H-Score mean results were found to be significantly higher (p < .05). In addition, it was observed that there was an increase in neural tube patency and developmental delay. As a result, sugammadex crossing the placenta was revealed to increase the release of proapopitotic molecules and disrupt the developmental stages of embryos. Thus, it was determined that sugammadex in increased developmental delay and incidence of neural tube defects in early chick embryos with increased dose dependent. Despite these results, the effects of sugammadex on fetal development in in vivo and in vitro environments should be studied with further studies. RESEARCH HIGHLIGHTS: Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. It has been observed that different doses of sugammadex increase the risk of neural tube defect development on chick embryos and slow the embryo development in a dose-dependent manner.
苏伽达ex 是一种新型药物，它导致了麻醉实践的重大变化。然而，它对胎儿发育的影响尚未完全清楚。本研究旨在探讨苏伽达 ex 对早期鸡胚神经管和胚胎发育的致畸作用。本研究使用 50 枚 0 日龄的特定非致病性（SPF）受精鸡蛋。将 50 个鸡蛋分为 5 个不同的组，每组 10 个。在研究的第 28 小时，对照组未给予任何物质，而实验组分别给予 2、4、8、16mg/kg 的 4 种不同剂量的苏伽达 ex。比较各组胚胎的头尾长度、体节数、每个核的银染核仁形成区（AgNOR）数、总 AgNOR 面积/总核面积（TAA/NA）比值、Caspase-3 H 评分结果和神经管缺陷的存在。与对照组相比，胚胎的平均头尾长度、体节计数、TAA/NA 比值和 AgNOR 计数均显著降低，而 Caspase-3 H 评分均值显著升高（p<.05）。此外，还观察到神经管通畅性增加和发育延迟。结果表明，苏伽达 ex 穿过胎盘增加了促凋亡分子的释放，扰乱了胚胎的发育阶段。因此，确定苏伽达 ex 随着剂量的增加，早期鸡胚的发育延迟和神经管缺陷的发生率增加。尽管有这些结果，仍需要进一步的研究来研究苏伽达 ex 在体内和体外环境对胎儿发育的影响。研究亮点：苏伽达 ex 是一种新型药物，它导致了麻醉实践的重大变化。然而，它对胎儿发育的影响尚未完全清楚。观察到不同剂量的苏伽达 ex 增加了鸡胚神经管缺陷发育的风险，并以剂量依赖的方式减缓了胚胎发育。
